The potentially pathogenic effects of infection with Epstein-Barr virus (EBV), a B-lymphotropic agent with cell growth-transforming potential, are contained in healthy virus carriers by viruspecific cytotoxic T-lymphocyte (CTL) 
2, EBNA 3a, EBNA 3c, and EBNA leader protein-have been introduced into vaccinia virus vectors under control of vaccinia promoter P7.5 and used to express relevant EBNA proteins in appropriate target cells. Thus the CTL response from one donor has been mapped to type A EBNA 2 protein and from a second donor to type A EBNA 3a protein. Thereafter, a series of recombinant vaccinia viruses were constructed that carried specific internal deletions within the EBNA 2 type A coding sequence; by using these vectors, the above EBNA 2 type A-specific CTL response was shown to be directed against an epitope within a 100-amino acid fragment near the N terminus ofthe protein. This work clearly shows human CTL recognition of virus-coded nudear antigens in the EBV system; moreover, it establishes an experimental approach that can be extended to all EBV latent proteins and to the more common CTL responses that cross-react against type A and type B virus isolates.
Epstein-Barr virus (EBV), a human herpesvirus with potent growth-transforming activity in B lymphocytes, causes infectious mononucleosis and is strongly linked with two B-cell malignancies, endemic Burkitt lymphoma and the oligoclonal lymphomas to which immunologically compromised patients are especially prone (1) . In healthy virus carriers, EBVspecific HLA antigen-restricted cytotoxic T lymphocytes (CTLs) appear important in controlling the virus infection in the B-cell system (2) , and therefore determining the target antigens against which such CTL responses are directed is important. In this context EBV-transformed B cells, growing in vitro as lymphoblastoid cell lines (LCLs), constitutively express a limited number of virus gene products, the socalled virus latent proteins. These include six EBV nuclear antigens (EBNAs), EBNA 1, 2, 3a, 3b, 3c, and leader protein (EBNA-LP); a latent membrane protein (LMP), and possibly a second membrane-associated product, LMP-2 or terminal protein (3, 4) . Any one of these proteins could potentially provide peptide epitopes for EBV-specific CTL recognition.
There are two distinct families of EBV isolate, types A and B, the existence of which was first recognized by allelic polymorphisms in the EBNA 2 coding'sequence, producing EBNA (11) ; the partial EBNA 3a coding sequence was cloned into a related plasmid pGS62 (12) , whereas EBNA 2A DNA was inserted into p62M, a transfer vector made by inserting a polylinker into the BamHI-EcoRI site of plasmid pGS62, such that the inserted coding sequence was in frame with an initiating ATG. In each case, the EBV sequences were positioned downstream of the vaccinia P7.5 early-late promoter, which is the promoter of choice for expressing target proteins for CTL recognition (13) . Vaccinia virus recombinants were generated according to Chakrabati et al. (11) 
EBNA3a-EBNA2
,-type A --type B published methods (14) . Expression of EBNA 2A and 2B proteins was assayed by using mouse monoclonal antibody (mAb) PE2 (15), EBNA-LP was assayed by using mAb JF186 (16) , and EBNA 3a and EBNA 3c were assayed by using affinity-purified antibodies from human serum RS22 (7) .
Source and Generation of CTL Populations. Two EBVimmune donors were used, JS (HLA Al, A2, B8, B51) and LC (HLA Al, B8, B18). The dominant EBV-specific CTL response of both donors has been shown to be selectively directed against autologous type A virus-transformed cells (8, 17) . Polyclonal CTL lines and CTL clones generated by seeding in semisolid agarose were established from these donors and maintained as described (8) . All CTL clones were CD3+ CD4-CD8+.
Cytotoxicity Assays on Recombinant Vaccinia VirusInfected Targets. Type B virus-transformed LCLs were infected with recombinant vaccinia viruses at a moi of 10:1 as above. Four hours after infection, cells were pelleted and incubated with 51CrO4 for 1 hr, then washed three times, and used as targets in a standard 5-hr chromium release assay; the assay period was usually timed to run from 6 to 11 hr after infection. Effector CTLs were added to the assay at effector/ target ratios between 2:1 and 20:1. For each assay, expression ofthe relevant EBV protein in target cells was confirmed from protein extracts of the same recombinant vaccinia virus-infected cells made 6 hr after infection.
RESULTS
Individual vaccinia virus recombinants were generated carrying the coding sequences for EBNA 2A; type A EBNA 3a, EBNA 3c, and EBNA-LP proteins; and for EBNA 2B protein. The capacity ofthese recombinant viruses to express the relevant EBNA species was, in each case, confirmed by infecting EBV-negative TK-143 cells and, where appropriate, type B EBV-transformed LCLs of the kind used as targets in later cytotoxicity assays. By using a moi of 10, maximal levels of EBNA expression were achieved by 4 to 6 hr after infection for each recombinant virus and remained stable for at least 12 hr thereafter. Fig. 1 (Fig. LA) , Vacc-EBNA 3a and Vacc-EBNA 3c (Fig. 1B) , and Vacc-EBNA-LP (Fig. 1C ) recombinants, probed with the relevant monoclonal or monospecific antibody. EBNA 2A, EBNA 2B, and EBNA 3c were expressed as the predicted 85-kDa, 75-kDa, and 149-kDa proteins, respectively, at levels significantly higher than those found for the corresponding viruscoded proteins in reference LCLs. The Vacc-EBNA 3a recombinant (carrying the large BERFM exon ofthe EBNA 3a sequence) encoded a major 120-kDa molecule, which was slightly smaller than the full-length 142-kDa protein (BLRF3/ BERF1-encoded) in LCLs. EBNA-LP was strongly expressed as a ladder ofproteins in the 18-to 45-kDa region (see also Fig. 1 legend) ; such a ladder is also frequently seen in LCLs (16) , although the X50-7 type A LCL used as control in Fig. 1C gives unusually strong expression of one of the high-molecular-weight EBNA-LP species.
In initial cytotoxicity experiments, a polyclonal CTL population from donor JS with a predominant type A virusspecific cytotoxic component was assayed on autologous type B virus-transformed LCL cells infected with the above recombinant vaccinias and with a control vaccinia TKrecombinant. Fig. 2 illustrates the clear pattern of results reproducibly obtained with this particular CTL population and also with a second polyclonal CTL line prepared from the same donor. Expression of EBNA 2A in the type B LCL led to lysis at levels at least as high as that seen with autologous type A virus-transformed target cells, whereas these same targets infected with the other recombinant vaccinias were never recognized. Other effector/target combinations included as controls in the same experiments confirmed that sensitization through EBNA 2A was specific to the autologous JS effector/target combination (Fig. 2 legend) . Fig. 3A is because this deletion removes the epitope recognized by mAb PE2; presence of truncated EBNA 2A in these cells was confirmed by using a relevant polyclonal human serum (data not shown). In addition, immunofluorescence staining with mAb PE2 or with selected human sera showed that all truncated EBNA 2A proteins still localized to the nucleus ofinfected cells, although the nuclear staining patterns differed. EBNA 2-deletion (del) St and -del PP gave granular staining like that of the wild-type protein, EBNA 2-del BB and -del Sp produced larger more discrete aggregates (4-10 per nucleus) relative to wild type, whereas EBNA 2-del HB gave diffuse staining throughout the nucleus but spared the nucleolus (data not shown).
Three independent CTL clones derived from donor JS and showing type A-specific recognition were assayed on the autologous type B virus-transformed LCL after its infection with the above panel of recombinant vaccinia viruses. Fig. 4 illustrates the results obtained from one such clone; two other clones and the polyclonal line from donor JS described in Fig.  2 also consistently gave the same pattern of reactivity. Four ofthe vaccinia-deleted EBNA 2A recombinants produced the same sensitization to CTL lysis as the Vacc-full-length EBNA 2A recombinant; in contrast the Vacc-A and Vacc-HB recombinant viruses produced no sensitization. It was significant that these latter two recombinant viruses were distinct from all others in having overlapping deletions affecting a region near the N terminus of EBNA 2A protein (see Fig. 3B ).
A final series of experiments was conducted with CTL clones derived from a second donor, LC, whose EBVspecific CTL response was similarly dominated by a type A virus-directed component. Here again the autologous type B virus-transformed LCL was tested for CTL recognition after its infection with vaccinia recombinants expressing the various type A EBNA proteins. Results from one such CTL clone, shown in Fig. 5 , represent those obtained with all eight individual clones tested from donor LC. In this case, clear sensitization was seen after infection with the EBNA 3a-encoding vaccinia recombinant, producing levels of lysis even higher than seen for the autologous type A virustransformed LCL in the same experiment. Once again allogeneic effector/target combinations included as controls confirmed specificity of the above recognition (see Fig. 5 legend). DISCUSSION EBV-induced growth transformation of resting B cells to LCLs is associated with the expression of a limited number of virus genes encoding the virus latent proteins (3, 4) and also with a dramatic change in cellular gene expression such that the infected cells assume a lymphoblastoid phenotype and constitutively express high levels of cell-surface activation antigens (18) and adhesion molecules (19) . Accordingly, conjugate formation between these target cells and CTLs (19) . Hence cellular changes play an important role in senialysis of CTL clone 6 from donor JS, sitizing infected B cells to CTL lysis by facilitating.cell-cell imulation as described in Fig. 2 (Fig. 4) . Omitting the polyproline sequence, which constitutes more than one-third of this fragment in EBNA 2A and is much shorter in EBNA 2B, the fragment differs in 15 amino acids between EBNA 2A and EBNA 2B (5 (17) .
Additional studies strongly suggest that the CTL responses from donors LC and JS described here are restricted through different HLA class I antigens. For EBNA 3a-specific clones from donor LC (HLA-A1, -B8, -B18) restriction is through HLA-B8 (17) . For EBNA 2-specific clones from donor JS (HA-Al, A2, B8, B51) the restricting element has not been unequivocally identified; however, it appears to be an HLA class I antigen other than HLA-B8 because lysis of the autologous type A LCL is blocked by mAbs to an HLA class I framework determinant (8) (8, 24) . By extending the experimental approach described here, identification of the immunodominant EBV latent proteins for such cross-reactive responses should be possible.
